Integrated Wellness · Research education
Compare the science.
Put two to four molecules side by side. Similar goals do not mean similar mechanisms, evidence or risks.
Choose your molecules
4 of 4 selected · Choose at least 2
Explore a comparison:
On smaller screens, scroll the table sideways to see each molecule.
| Research dimension | Sermorelin Human research | CJC-1295 Human research | Ipamorelin Human research | GHRP-2 Human research |
|---|---|---|---|---|
| Biological classification | GHRH (1–29) analog | Long-acting GHRH analog | Synthetic pentapeptide secretagogue | Synthetic growth-hormone-releasing peptide (pralmorelin) |
| Mechanism & pathway | Acts at pituitary GHRH receptors to stimulate endogenous growth hormone release, with downstream IGF-1 signaling. A functioning hypothalamic-pituitary system and clinical context influence responses. | A synthetic growth hormone-releasing hormone analog. The long-acting DAC form binds albumin to prolong exposure and stimulates the GHRH receptor upstream of GH/IGF-1. | Stimulates GH release through ghrelin-receptor/secretagogue signaling, rather than the GHRH receptor. Selectivity reported in preclinical models does not guarantee absence of adverse effects in people. | Acts at the ghrelin receptor (GHS-R1a) to stimulate growth hormone release. Downstream endocrine responses depend on physiological context and can extend beyond GH alone. |
| Investigated applications | Pituitary GH response and historical pediatric GH-deficiency research. | GH and IGF-1 responses and pharmacokinetics in controlled research. | GH signaling and gastrointestinal motility research. | Human endocrine responses and GH-stimulation testing. |
| Evidence quality | Human research | Human research | Human research | Human research |
| What remains uncertain | The linked article is a commentary, not a randomized anti-aging trial. Historical Geref approval and discontinuation do not make current compounded formulations FDA-approved. | The cited trial studies the long-acting DAC form and hormone responses, not proof of improved recovery or anti-aging benefit. Modified GRF (1–29) without DAC is not interchangeable. | The foundational linked study is preclinical. A separate human postoperative-ileus trial does not establish anti-aging or recovery benefit. | Diagnostic or hormone-response research does not establish performance benefits. Non-US diagnostic use is not US FDA approval. |
| Safety considerations | Potential endocrine effects, glucose changes, fluid retention and hypersensitivity require clinical assessment. Long-term anti-aging use lacks adequate evidence. | Potential glucose intolerance, fluid retention and endocrine effects; FDA reports increased heart rate and systemic vasodilatory reactions. | FDA notes serious adverse events including deaths in an intravenous motility study and insufficient safety information for other injectable routes; this does not by itself establish causality. | Endocrine and glucose effects are concerns. FDA describes serious adverse-event reports including infection and pancreatitis; causality was not established. |
| Regulatory classification | Historical FDA product · discontinuedGeref was historically FDA-approved and later discontinued; FDA determined withdrawal from sale was not for safety or effectiveness reasons. Current compounded preparations are not FDA-approved finished drugs. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. |
Comparing molecules is not a recommendation to combine them. Clinical evidence for one product or indication cannot establish another’s safety or effectiveness. Open each profile for study types, source links and important evidence limitations.